CRD-102 / Avacta - LARVOL DELTA

Lenalidomide induction and maintenance therapy for transplant eligible myeloma patients: Results of the Myeloma XI study. (ASCO 2017) - P3; "...For TE patients the induction question compared Len or Thal plus cyclophosphamide and dexamethasone (CRD vs CTD) continued for a minimum of 4 cycles and to max...2042 TE patients underwent the induction randomization (CRD 1021, CTD 1021)... CRD was associated with deeper responses than CTD, and with a PFS and OS benefit. The best outcomes were associated with Len induction plus Len maintenance. Our findings support continuing Len therapy through induction until disease progression."

Clinical • Biosimilar • Multiple Myeloma

CRD-102 for Right Heart Failure in Patients With Left Ventricular Assist Devices (clinicaltrials.gov) - P1/2; N=10; Recruiting; Sponsor: Cardiora Pty. Ltd.; Not yet recruiting ➔ Recruiting; Initiation date: Aug 2017 ➔ Feb 2018

Enrollment open • Trial initiation date • Biosimilar • Cardiovascular • Heart Failure

CRD-102 for Right Heart Failure in Patients With Left Ventricular Assist Devices (clinicaltrials.gov) - P1/2; N=10; Not yet recruiting; Sponsor: Cardiora Pty. Ltd.

New P1/2 trial • Biosimilar • Cardiovascular • Heart Failure

Extended Release Oral Milrinone, CRD-102, for Advanced Heart Failure. (PubMed, Am J Cardiol) - "In conclusion, the present study demonstrates evidence of beneficial actions of extended release milrinone in advanced HF. Longer-term randomized clinical trial data are required."

Journal

CRD-102 for Right Heart Failure in Patients With Left Ventricular Assist Devices (clinicaltrials.gov) - P1/2; N=6; Completed; Sponsor: Cardiora Pty. Ltd.; Recruiting ➔ Completed; N=10 ➔ 6; Trial primary completion date: Apr 2019 ➔ Oct 2018

Clinical • Enrollment change • Trial completion • Trial primary completion date

CRD-102 for Right Heart Failure in Patients With Left Ventricular Assist Devices (clinicaltrials.gov) - P1/2; N=10; Recruiting; Sponsor: Cardiora Pty. Ltd.; Trial completion date: Aug 2018 ➔ May 2019; Trial primary completion date: Aug 2018 ➔ Apr 2019

Clinical • Trial completion date • Trial primary completion date